![Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial - The Lancet Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/4674c273-ee8e-4d09-9468-d333c7522490/gr1.gif)
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial - The Lancet
![PDF) Inhalation treatment of lung cancer: the influence of composition, size and shape of nanocarriers on their lung accumulation and retention PDF) Inhalation treatment of lung cancer: the influence of composition, size and shape of nanocarriers on their lung accumulation and retention](https://i1.rgstatic.net/publication/261745797_Inhalation_treatment_of_lung_cancer_the_influence_of_composition_size_and_shape_of_nanocarriers_on_their_lung_accumulation_and_retention/links/0a85e539756b2cc062000000/largepreview.png)
PDF) Inhalation treatment of lung cancer: the influence of composition, size and shape of nanocarriers on their lung accumulation and retention
![New Finding Could Predict Which People with Lung Cancer Will Benefit from Chemotherapy | Memorial Sloan Kettering Cancer Center New Finding Could Predict Which People with Lung Cancer Will Benefit from Chemotherapy | Memorial Sloan Kettering Cancer Center](https://www.mskcc.org/sites/default/files/styles/large/public/node/234817/3x2/adusumilli-prasad_210914_010-1200x800.jpg)
New Finding Could Predict Which People with Lung Cancer Will Benefit from Chemotherapy | Memorial Sloan Kettering Cancer Center
![SOD1 regulates ribosome biogenesis in KRAS mutant non-small cell lung cancer | Nature Communications SOD1 regulates ribosome biogenesis in KRAS mutant non-small cell lung cancer | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-021-22480-x/MediaObjects/41467_2021_22480_Fig1_HTML.png)
SOD1 regulates ribosome biogenesis in KRAS mutant non-small cell lung cancer | Nature Communications
![Advanced Metastatic Non-Small Cell Lung Cancer Information | ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) Advanced Metastatic Non-Small Cell Lung Cancer Information | ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound)](https://abraxane.com/wp-content/uploads/2015/09/disease1.jpg)
Advanced Metastatic Non-Small Cell Lung Cancer Information | ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound)
![24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer - Journal of Thoracic Oncology 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer - Journal of Thoracic Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/8909c5a9-ab2e-4cb0-9e07-6d3dab4314fb/gr1_lrg.jpg)
24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer - Journal of Thoracic Oncology
![Bristol Myers Squibb's Opdivo posts another win in early lung cancer, but debate over treatment approach likely remains | FiercePharma Bristol Myers Squibb's Opdivo posts another win in early lung cancer, but debate over treatment approach likely remains | FiercePharma](https://qtxasset.com/styles/breakpoint_sm_default_480px_w/s3/fiercepharma/1636383854/FierceImages-Opdivo3.jpg/FierceImages-Opdivo3.jpg?VersionId=qLCyry4cN4.sE.GgT1fGkTjCkykCv7Of&itok=bQeJS2BM)
Bristol Myers Squibb's Opdivo posts another win in early lung cancer, but debate over treatment approach likely remains | FiercePharma
![Systemic Treatment Patterns With Advanced or Recurrent Non–small Cell Lung Cancer in Japan: A Retrospective Hospital Administrative Database Study - Clinical Therapeutics Systemic Treatment Patterns With Advanced or Recurrent Non–small Cell Lung Cancer in Japan: A Retrospective Hospital Administrative Database Study - Clinical Therapeutics](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/addd87dd-e0df-429f-ba86-1299b527ead8/gr3.jpg)
Systemic Treatment Patterns With Advanced or Recurrent Non–small Cell Lung Cancer in Japan: A Retrospective Hospital Administrative Database Study - Clinical Therapeutics
![Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer - Journal of Thoracic Oncology Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer - Journal of Thoracic Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/0049bf76-c153-4c19-b434-4f0e53df4489/gr1.jpg)